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Abstract
Background: Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and
the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage.
Thus, the concomitant use of novel compounds represents a critical strategy to improve treatment results. Histone
deacetylase inhibitors (HDACi) enhance the activity of several anticancer drugs including cisplatin and anti-Epidermal
Growth Factor Receptor (anti-EGFR) compounds. Preclinical studies in models have shown that vorinostat is able to
down regulate Epidermal Growth Factor Receptor (EGFR) expression and to revert epithelial to mesenchimal transition
(EMT). Due to its histone deacetylase (HDAC) inhibiting activity and its safe use as a chronic therapy for epileptic
disorders, valproic acid (VPA) has been considered a good candidate for anticancer therapy. A reasonable option may
be to employ the combination of cisplatin, cetuximab and VPA in recurrent/metastatic SCCHN taking advantage of the
possible positive interaction between histone deacetylase inhibitors, cisplatin and/or anti-EGFR.
Method/Design: V-CHANCE is a phase 2 clinical trial evaluating, in patients with recurrent/metastatic squamous cell
carcinoma of the head and neck never treated with first-line chemotherapy, the concomitant standard administration
of cisplatin (on day 1, every 3 weeks) and cetuximab (on day 1, weekly), in combination with oral VPA given daily from
day −14 with a titration strategy in each patient (target serum level of 50–100 μg/ml). Primary end point is the
objective response rate measured according to Response Evaluation Criteria in Solid Tumors (RECIST). Sample size,
calculated according to Simon 2 stage minimax design will include 21 patients in the first stage with upper limit
for rejection being 8 responses, and 39 patients in the second stage, with upper limit for rejection being 18
responses. Secondary endpoints are time to progression, duration of response, overall survival, safety.
Objectives of the translational study are the evaluation on tumor samples of markers of treatment efficacy/
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resistance (i.e. γH2AX, p21/WAF, RAD51, XRCC1, EGFR, p-EGFR, Ki-67) and specific markers of VPA HDAC inhibitory
activity (histones and proteins acetylation, Histone deacetylase isoforms) as well as valproate test, histones and
proteins acetylation of peripheral blood mononuclear cell, tested on blood samples at baseline and at different
time points during treatment.
Discussion: Overall, this study could provide a less toxic and more effective first-line chemotherapy regimen in
patients with recurrent/metastatic squamous cell carcinoma of the head and neck by demonstrating the feasibility and
efficacy of cisplatin/cetuximab plus valproic acid. Moreover, correlative studies could help to identify responder
patients, and will add insights in the mechanism of the synergistic interaction between these agents.
EudraCT Number: 2014-001523-69
Trial registration: ClinicalTrials.gov number, NCT02624128
Keywords: Cetuximab, Cisplatin, Head and Neck cancer, Histone deacetylase inhibitor, Valproic acid
Background
Histone deacetylases inhibitors (HDACi) as anticancer
agents
Epigenetic alterations, such as hypoacetylation of
histones, play an important role in initiation and
progression of several cancers, including squamous
cell carcinoma of the head and neck (SCCHN). Since
epigenetic alterations are dynamic and generally re-
versible, epigenetic manipulation has emerged as an
attractive novel anticancer treatment. Histone Deace-
tylase inhibitors (HDACi) are emerging epigenetic
antitumor agents [1]. A large number of HDACi are
currently in clinical development as anticancer
agents, and three (vorinostat, romidepsin and belino-
stat) have been approved by the US FDA for the
treatment of cutaneous T-cell lymphoma [2, 3],1
while panobinostat is the first HDAC inhibitor ap-
proved to treat multiple myeloma in combination
with the proteasome inhibitor bortezomib and dexa-
methasone, in patients who have received at least
two prior standard therapies.2 Our group and many
others have demonstrated the synergistic antitumor
activity of HDACi in combination with several che-
motherapeutics and molecular targeted agents, in-
cluding cisplatin and anti-epidermal growth factor
receptor (EGFR) agents [4–7]. In details, we have re-
cently demonstrated that the HDACi vorinostat, in
combination with the EGFR-tyrosine kinase inhibitor
gefitinib, induced synergistic inhibition of prolifera-
tion, migration and invasion as well as induction of
apoptosis, in preclinical models of SCCHN, including
cancer cell lines resistant to gefitinib and character-
ized by mesenchymal markers and phenotype. The
mechanism of the synergistic interaction is related to
the ability of vorinostat to modulate the expression
and the activity of ErbB receptors (EGFR, ErbB2 and
ErbB3) and to reverse the epithelial mesenchymal
transition (EMT) in gefitinib-resistant cells [5].
Valproic acid: preclinical and clinical studies
Valproic acid (VPA), an anticonvulsant clinically effect-
ive also as a mood stabilizer in the treatment of maniac
depression (bipolar affective disorder) has HDAC inhibi-
tory activity and anticancer properties with good safety
profile compared with other HDACi [8, 9].
The recommended values of serum concentrations
for epilepsy treatment are in the 50–100 μg/ml range.
Phase-1/2 studies in several malignancies showed that
VPA, either as a monotherapy or in combination with
other agents, was well tolerated with some encouraging
responses. In monotherapy at oral doses between 20 and
60 mg/kg VPA inhibit deacetylase activity in solid tumors
[10]. VPA oral doses of 30 mg/kg daily in combination
with the demethylating agent hydralazine, doxorubicin
and cyclophosphamide, as neoadjuvant therapy in lo-
cally advanced breast cancer patients, was safe and
tumor responses appeared higher as compared with
historical controls; HDAC inhibition was demonstrated
in the peripheral blood of the patients, with a mean
plasma concentration of 87.5 μg/ml [11]. In another
phase I/II trial, VPA in combination with chemotherapy
(FEC100) for patients with solid tumors, demonstrated
a maximum tolerated dose (MTD) of 140 mg/kg/day
with nine patients achieving a partial response. During
the second part of the study, a disease-specific cohort
breast cancer patients were treated with VPA 120 mg/
kg/day plus FEC100 regimen; 9 out of 14 patients
responded and somnolence was the most noted VPA-
related adverse effect [12]. Notably, VPA crosses the
blood–brain barrier, and can be safely utilized for long
time frames. All the above characteristics point to VPA
as an appealing drug for clinical studies.
VPA is one of the most studied HDACi in combin-
ation therapy with platinum-based drugs in many cancer
cell models including SCCHN [8]. Currently valproate is
being evaluated in combination with cisplatin in a phase
2 clinical trial in refractory and recurrent mesothelioma
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patients [13]. We have recently launched a Phase ½
clinical study of VPA in combination with capecita-
bine and short-course radiotherapy as preoperative
treatment in locally advanced rectal cancer patients
(EudraCT Number: 2012-002831-28) [14].
VPA safety and cardiac toxicity
Common toxicities demonstrated by almost all HDAC
inhibitors including thrombocytopenia, neutropenia,
diarrhea, nausea, vomiting and fatigue, were not re-
ported for VPA treatment, being somnolence the only
dose-limiting adverse effect. Several additional mild
and transient side effects were described for VPA but
most of them were related with its chronic use [15].
In details, weight gain, changes in serum triglycerides,
cholesterol and fast glucose were described, as well as
some dermatological effects such as stomatitis, cuta-
neous leukocytoclastic vasculitis and psoriasis-like
eruption. Due to its direct neurological action some
rare neurological side effects were also reported in-
cluding encephalopathy, VPA-induced parkinsonism,
and hyperammonemia in the absence of liver failure.
Hepatotoxicity has been also reported particularly in
young children and in the presence of hepatic disorders.
Finally, one study reported the increased risk of aplastic
anemia after the use of VPA, but opposite evidences re-
ported VPA as a potent activator of erythropoiesis in epi-
leptic patients.
Extensive studies have been performed to determine
whether HDAC inhibitors are associated with cardiac
toxicities [2, 16–19]. In a phase I trial of VPA in combin-
ation with epirubicin, a grade 2 QTc prolongation was
reported in eight patients (18%), and a grade 3 QTc pro-
longation was seen in two patients (5%); these events oc-
curred predominantly on day 1 of VPA treatment. QTc
prolongations were associated with serum potassium
levels less than 4.0 mmol/L and were resolved in all pa-
tients with appropriate potassium and magnesium sup-
plementation [20].
Rationale
Combination of an HDAC inhibitor with anti EGFR agent
and platinum derivatives in SCCHN
SCCHN accounts for 6–7% of all malignancies, repre-
senting the fifth most common tumor worldwide. About
50% of the patients who have been treated for an early
stage or a locally advanced disease, will experience a re-
current and/or metastatic disease. Albeit several therapy
improvements have been registered in the last years, the
prognosis of patients with recurrent/metastatic disease
remains poor, particularly for those with the traditional
risk factors of tobacco and/or alcohol use as compared
with patients with human papilloma virus (HPV)-driven
disease. The application of targeted therapeutics in
SCCHN has been disappointing to date as compared to
other cancer types. A number of additional therapeutic
targets have been proposed for SCCHN based on recent
genomic discovery studies and preclinical studies but
none have been confirmed so far in clinical studies
[21]. Cisplatin is the mainstay of combinatory treat-
ment for several solid tumors, including unresectable
and recurrent/metastatic SCCHN. This drug is often
associated with the antimetabolite 5-fluorouracil (5FU),
showing a good anti-cancer response but also many
toxic effects as well as treatment-resistance. Overex-
pression of EGFR and of its ligands TGF-α or EGF has
been observed in about 90% of SCCHN specimens,
with the exception of HPV-positive tumors, and corre-
lates with poor disease-free and overall survival, an in-
creased risk of disease recurrence and metastasis, and
resistance to chemotherapy, including cisplatin, and
radiotherapy [22]. Interestingly, it was previously re-
ported that EGFR over-expression has an important
role in the induction of resistance to cisplatin treat-
ment. In details, it has been demonstrated that tumor
cells treated with cisplatin show increased EGFR activa-
tion which can be considered a survival response to the
treatment [23].
Therefore, EGFR is considered to be an excellent tar-
get for this disease, and the anti-EGFR monoclonal anti-
body cetuximab (CTX), although yielding only modest
clinical activity in monotherapy, is the only targeted
therapy approved for the treatment of SCCHN in pa-
tients with locally advanced tumors in association with
radiotherapy and in patients with recurrent or metastatic
disease in combination with cisplatin-based chemother-
apy [22, 24–26].
In addition, the transdifferentiation of epithelial cells
into mesenchymal cells, known as EMT, a key process re-
quired during embryonic development and associated
with the development of invasive cancer [27], seems also
to play a role in the resistance to EGFR TKIs in several tu-
mors, including SCCHN [28]. Moreover, a mesenchymal-
enriched subtype represents a distinct type of SCCHN
with a defined recurrence-free survival prognosis.
Our group and many others have demonstrated the
synergistic antitumor activity of HDACi in combin-
ation with a large number of structurally different an-
ticancer agents, among which cisplatin and anti-EGFR
agents [4–7]. Our group has recently demonstrated
that the HDACi vorinostat, in combination with the
EGFR-tyrosine kinase inhibitor gefitinib, induced syn-
ergistic inhibition of proliferation, migration and inva-
sion as well as induction of apoptosis, in preclinical
models of SCCHN and NSCLC, including cancer cell
lines resistant to gefitinib and characterized by mes-
enchymal markers and phenotype. The mechanism of
the synergistic interaction is related to the ability of
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vorinostat to modulate the expression and the activity
of ErbB receptors (EGFR, ErbB2 and ErbB3), to re-
verse EMT, and/or to alter redox homeostasis in
gefitinib-resistant cells [5, 7, 29].
VPA is one of the most studied HDACi in combin-
ation therapy with platinum-based drugs in many cancer
cell models including SCCHN [8]. Currently valproate is
being evaluated in combination with cisplatin in a phase
II clinical trial in refractory and recurrent mesothelioma
patients [13].
Biomarkers study
SCCHN, given the relative accessibility of tumor to sam-
ple, is an ideal cancer type to assess the efficacy of new
therapeutic approach with biopsy samples taken before
and during treatment to identify biomarkers of response
and resistance.
VPA serum levels was correlated in several studies
with histone acetylation in tumor samples and in
PBMC and was also linked to baseline expression of
HDAC isoforms. In oral tongue cancer (generally
HPV-negative) it has been demonstrated that HDAC1
and 2 are overexpressed and associated with signifi-
cantly shorter progression-free survival (PFS) [30].
Moreover, in several clinical studies the measurement
of histone acetylation on PBMC has been studied as
a surrogate marker of HDACi activity; however, in
most cases this measurement has not been success-
fully linked to clinical outcome. Recently Yardley
et al., have analyzed protein lysine acetylation in pre-
and post-treatment samples collected in a subset of
49 breast cancer patients treated with the combin-
ation of the HDACi entinostat plus exemestane dem-
onstrating that hyperacetylation of protein lysines in
PBMC was associated with improved clinical out-
come, as shown by the prolonged PFS in hyperacety-
lators versus low acetylators [31]. Elevated levels of
protein lysine acetylation maintained in certain pa-
tients despite entinostat levels at or below the level of
detection at the time of sampling seem to reflect the
durability and potency of the pharmacodynamic ef-
fects that low sustained concentrations of entinostat
can elicit. Biomarker studies in clinical trials have
shown that, besides histone hyperacetylation, the
major effects of HDAC treatment in solid tumors
were p21 overexpression and Ki-67/MIB-1 downregula-
tion, two features typically related with cell differentiation
and growth arrest. As mentioned above, HDAC inhibitor
can sensitize cancer cells to cisplatin by different mecha-
nisms including the regulation of the expression of DNA
repair genes such as RAD51 [32] and the downregulation
of antiapoptotic genes such as BCL2 and XIAP [8]. There
are evidences that cancer with moderate expression of
EGFR are more sensitive to CTX compared with those
that express very high levels of EGFR [33]. Preclinical
study showed CTX resistant cell line express not only
increase in EGFR but in also other members of the
same family and in particular HER2 and HER3 as
well as MET. HER4 has been observed overexpressed
in some HNSCC cancer cell lines where it is associ-
ated with higher proliferative rate [34]. It has been
observed that MET expression represent an independ-
ent predictor of reduced disease-free and overall sur-
vival in HNSCC patients [35]. Even more compelling
are data that correlate MET expression and radiation
[35], cisplatin [36, 37] and CTX [38] in SCCHN. The
majority of SCCHN (>90%) overexpress the epidermal
growth factor receptor (EGFR or HER1) HER1, which
correlates with a poor prognosis and overall resistance
to therapy. Immunotherapy with the EGFR-specific
IgG1 mAb, CTX, significantly improves survival of
SCCHN patients with advanced or metastatic disease
[25]. The available evidence is consistent with the
possibility that the beneficial effects of CTX adminis-
tration on the clinical course of the disease reflect
both inhibition of EGFR tyrosine phosphorylation and
triggering of antibody-dependent, cell-mediated cyto-
toxicity (ADCC) of SCCHN cells [39]. Binding of
CTX to the EGFR leads to internalization and degrad-
ation of the antibody–receptor complex and down-
regulation of EGFR expression [33]. Also CTX can
activate immune cells that bear receptors for the Fc
(constant portion) of IgG such as natural killer (NK)
cells. NK cells have an activating Fc receptor for IgG
(FcγRIIIa), which mediates Ab dependent cellular
cytotoxicity (ADCC) and enhances production of
interferon-γ (IFN-γ) in response to Ab-coated targets
[40, 41]. We previously demonstrated that FcγRIIIa
polymorphisms were significantly associated with re-
sponse to anti-EGFR-based therapy in 49 colorectal
cancer patients with KRAS wt tumors, The results
suggested that prognosis is particularly unfavorable
for patients carrying the FcγRIIIa-158F/F genotype [42].
Methods/Design
V-CHANCE is a phase 2 trial exploring the feasibility and
the activity of VPA in combination with the standard
Cisplatin-Cetuximab in recurrent/metastatic SCCHN
never treated with first-line chemotherapy patients. The
study includes an explorative analysis of the potential
prognostic or predictive role of several biomarkers with
the aim of improving the knowledge of the mechanisms
by which VPA enhances chemotherapy effect and of iden-
tifying early predictors of treatment response/resistance.
Objectives
The primary objective of the study is to assess whether
VPA, given concomitantly with the conventional cisplatin-
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cetuximab regimen, can improve treatment activity (in
terms of objective response rate) in patients with recur-
rent/metastatic SCCHN.
Secondary objectives are response duration, time to
progression, overall survival, safety.
A translational study is also planned with several objec-
tives: (a) to compare the expression of several biomarkers
(p21/WAF, p16/INK4 and Ki-67/MIB-1, histones and pro-
teins acetylation (H&P-Ac), HDAC isoforms) in the tumor
and normal mucosa, to evaluate the tumor expression of
markers of treatment efficacy/resistance (pEGFR, MET,
RAD51, XRCC1, Bcl2 and XIAP γH2AX, VEGF). (b) to
evaluate Histones and proteins acetylation on PBMC as
additional surrogate pharmacodynamic markers of VPA
activity at different time points during and after treatment.
(c) to ensure achievement of the target serum level range,
performing valproate test, and to compare it with histones
and proteins acetylation.
Ethical aspects
The procedures set out in this study protocol are de-
signed to ensure that the principles of the Good Clinical
Practice guidelines of the International Conference on
Harmonization (ICH) and the Declaration of Helsinki
are respected in the conduct, evaluation and documenta-
tion of this study. The study was approved by the Inde-
pendent Ethical Committee (CEI) of the National Cancer
Institute of Naples, Italy (Clearence obtained with prot. N.
CEI/304/14, 17.07.2014). Patients provide written in-
formed consent for participating in the study and for
allowing to collect tissue and blood samples.
Study design
V-CHANCE is a phase 2 study performed in patients
with recurrent/metastatic SCCHN never treated with
first-line chemotherapy. Patients will be treated with cis-
platin (75 mg/m2 on day 1 to be repeated every 21 days),
CTX (loading dose of 400 mg/m2 followed by a main-
tenance dose of 250 mg/m2 to be repeated weekly) and
VPA (increasing oral doses, from 500 mg/day on day
−14 until a full dose of 1500 mg at day 1, with a titration
strategy in a patient for a target serum level range of
50–100 μg/ml). RECIST criteria version 1.1 will be
employed with the aim to determine the response rate.
In particular, complete responses (CR) will be defined as
the total disappearance of all target lesions; partial re-
sponse (PR) will be observed when the sum of largest di-
ameters of the target lesions will decrease by at least
30%. A 20% increase in the sum of diameter of target le-
sions will qualify as progressive disease (PD). Stable dis-
ease will be defined as neither sufficient shrinkage to
qualify for PR nor sufficient increase to qualify for PD.
Overall response rate (ORR) will be calculated as the
sum of CRs and PRs; while disease control rate (DCR)
will correspond to the sum of PS, CRs and SDs).
Sample size calculation
Simon 2 stage minimax design will be used for this trial.
First stage sample size will include 21 patients and the
upper limit for first stage rejection of drugs will be eight
patients. Maximum sample size will be 39 patients with
the upper limit for second stage rejection being 18 pa-
tients. Patients have to be enrolled with the aim to dis-
tinguish between the null and alternative hypotheses,
with a significance level of 0.05 and a power of 80%.
Patient selection criteria
Inclusion criteria
Patients ≥ 18 years, diagnosed, histologically or cytologic-
ally, with squamous cell carcinoma of head and neck
(except nasopharynx) will be admitted in the study. Pa-
tients have to have first-line recurrent and/or metastatic
disease and no prior chemotherapy except for chemo-
radiation or induction chemotherapy followed by local
treatment given in the context of a curative strategy.
ECOG performance status ≤1 at study entry, a life
expectancy > 3 months, normal bone marrow reserve,
hepatic function, renal function, cardiac function are
additional inclusion criteria; effective contraception is
mandatory for both male and female patients if the risk
of conception exists; a written informed consent has to
be signed.
Exclusion criteria
Main exclusion criteria are the following: Concomitant
treatment with other experimental drugs; brain metasta-
ses (CT scan or MRI required only in case of clinical
suspicion of CNS metastases); non-squamous cell hist-
ology; any concurrent malignancy (patient with a previ-
ous malignancy but without evidence of disease for
5 years will be allowed to enter the trial); history of myo-
cardial infarction within the last 12 months; significant
cardiovascular comorbidity; patients with long QT-
syndrome, or QTc interval duration > 480 msec, or con-
comitant medication with drugs prolonging QTc; known
or suspected hypersensitivity to any of the study drugs;
patient who have had prior treatment with an HDAC in-
hibitor and patients who have received compounds with
HDAC inhibitor-like activity, such as VPA; major surgi-
cal procedure, within 28 days prior to study treatment
start; patients who cannot take oral medication, who re-
quire intravenous feeding, have had prior surgical proce-
dures affecting absorption, or have active peptic ulcer
disease; pregnant or lactating women and sexually active
males and females (of childbearing potential) unwilling
to practice contraception during the study.
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Treatment plan
Treatment with VPA includes a titration strategy applied
in each patient looking for a serum concentration that is
considered useful to produce the desired synergistic ef-
fect with cisplatin and CTX. Treatment will be adminis-
trated orally starting at day −14 with a 500 mg slow
releasing tablet at evening. Thereafter, the dose will be
increased also using 300 mg tablets (Table 1).
In the morning of day −4, within 2 h after taking the
morning dose, serum level of VPA will be checked using
a commercially available valproate test, and will be ad-
justed depending on the reached steady level. The target
serum level range will be 50–100 μg/ml which repre-
sents the recommended values for the treatment of epi-
lepsy. At any time, in case of grade 2 somnolence or
fatigue the VPA dose will be reduced by 200 mg/day
steps up to reaching grade ≤1 independently of the actual
serum level. In case of grade ≥3 somnolence or fatigue
VPA will be definitely discontinued. In case of asymptom-
atic QTc prolongation development (QTc >500 ms, or QT
prolongation >600 ms,) VPA has to be interrupted. Elec-
trolytes and concomitant medications have to be checked
and corrected. ECG has to be repeated after 24 h. If the
event is resolved, treatment with VPA can be resumed but
the dose will be reduced by −200 mg/day; on the contrary,
if QT prolongation is confirmed VPA has to be inter-
rupted [43, 44]. In case of symptomatic QTc prolongation
development (QTc > 500 ms or QT prolongation >
600 ms,) and association with symptoms suggestive of a
ventricular tachyarrhythmia, VPA has to be interrupted.
At day 1 cisplatin at dose of 75 mg/m2 given every 3
weeks and CTX at induction dose of 400 mg/m2 followed
by maintenance doses of 250 mg/m2 given weekly, will be
administered. Adequate intravenous hydration will be re-
quired prior and after cisplatin administration. Antiemetic
prophylaxis with dexamethasone and palonosetron before
cisplatin will be also administered. Toxicity due to cis-
platin administration may be managed by symptomatic
treatment, dose interruptions and dose adjustment. Once
the dose has been reduced it should not be increased at a
later time. Doses of cisplatin omitted for toxicity are
not replaced or restored. At the time of recycling,
blood tests have to be normal (Absolute Neutrophil
Count 1.5 × 109/L, platelets 100 × 109/L). If lower values,
or at least grade 2 non-hematologic toxicities, are de-
tected, treatment will be interrupted and restored when
toxicity is back to grade 1, treatment will be restarted at
the same drug dosage. If at any time during a chemother-
apy cycle febrile neutropenia, grade 4 neutropenia, grade
4 thrombocytopenia, non-hematologic grade 3 toxicities
occur, the subsequent chemotherapy doses will be admin-
istered with 50% of the initial dose. No primary prophy-
laxis with G-CSF is allowed, but secondary prophylaxis is
allowed.
Assessment and procedures
Assessment and procedures, including those for explora-
tory objectives (see below) are illustrated in Fig. 1. Briefly,
baseline procedures will include: HPV-test, full laboratory
tests evaluation, cardiologic assessment including ultra-
sonography, fiberoscopy and Computed Tomography scan
of head, neck, thorax and abdomen. Other tests may be
performed at the researcher’s discretion.
Each treatment cycle will last 21 days, including ad-
ministration of cisplatin and CTX on day 1, only CTX
repeated on days 8 and 15 and VPA will be given orally
throughout the entire cycle. A complete physical exam
and a complete serum evaluation of blood cell count,
electrolytes, renal and liver function will be performed
weekly. Serum concentration of VPA will be assessed
every 2 weeks. A complete restaging will be performed
after three cycles of chemotherapy and will consist of
Computed Tomography scan of head, neck, thorax and
abdomen within 21 days from the last chemotherapy ad-
ministration, a new fibroscopy, a second evaluation of
H3 acetylation on blood mononuclear cells peripheral
extracted from a peripheral blood sample, a second
tumor biopsy in which immunohistochemical assay will
be done in order to evaluate marker modification upon
treatment. The last one will be performed at the end of
treatment (after 3 or 6 cycles) only in presence of meas-
urable and/or evaluable disease.
Toxicity evaluation criteria
Acute toxicity will be assessed weekly with clinical
examination and blood tests using Common Toxicity
Criteria for Adverse Events (CTCAE) of the National
Cancer Institute, version 4.0, June 14, 2010.
Response evaluation criteria
Response is assessed after 3 cycles. In case of CR, PR,
SD, 3 additional cycles will be given. Patients will receive
a maximum of 6 cycles. Follow-up tests were carried out
every 2 months, until progression.







−14 and −13 0 0 500
−12 and −11 300 0 500
−10 and −9 500 0 500
−8 and −7 500 300 500
−6 and −5 500 500 500
−4 and −3 500 500 500
−2 and −1 500 500 500
The interval between each dose will be 12 h from the −14 day to −9 day and
it will be 8 h from −8 day
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Biomarkers
Tumor biopsy and normal mucosa will be collected at
baseline (before starting VPA treatment) and possibly
within the diagnostic biopsy) at day −2, before starting
chemotherapy, and after 3 or 6 cycles of treatment at the
first or second evaluation only in presence of measurable
and/or evaluable disease. The following markers will be
measured: p21/WAF, p16/INK4 and Ki-67/MIB-1,
histones and proteins acetylation, as surrogate pharmaco-
dynamic markers of VPA activity on tumor; HDAC iso-
forms, only at baseline, as potential predictive markers of
VPA activity. The tumor expression of all the markers at
baseline will be compared with normal mucosa expression
and with the tumor expression after treatment. Moreover,
at baseline, at day −2 and eventually after 3–6 cycles (see
above), EGFR, p-EGFR, MET, RAD51, XRCC1, γH2AX,
will be measured as markers of treatment efficacy/resist-
ance evaluated by real-time PCR with the specific primers
and probes or by immunohistochemistry. Peripheral blood
samples will be collected at baseline, at day −4, 1, 8, at the
end of every cycle, at day 22 and at the end of treatment.
Histones and proteins acetylation on PBMC will be done
as additional surrogate pharmacodynamic markers of VPA
activity at different time points during and after treatment.
Valproate test will be performed to ensure achievement of
the target serum level range and to compare it with his-
tones and proteins acetylation.
Moreover, the CTX induced ADCC activity will be
evaluated at baseline by an in vitro assay according to
the previoulsy described methods [42] on PBMC and re-
sults will be correlated with polymorphisms of FcyRIIa-
H131R and the FcyRIIIa-V158F.
Statistical analysis
The overall response rate (ORR) will be calculated with
95% confidence interval. Time to progression, duration
of response and overall survival will be calculated from
the first treatment day until the day of event occurrence
(for OS the date of death or the date of termination of
the trial for patients alive at the time end of the study,
Fig. 1 Schematic timeline of study procedures. Note. History and physical examination, blood count, biochemistry will be repeated weekly
during treatment
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or the date of the last follow-up information available
for patients lost before the trial end date). Kaplan-
Meier methods will be used to estimate all time to
event endpoints. For each patient and type of toxicity,
the worst degree suffered during the treatment will
be described.
Due to the small sample size, statistical analysis of bio-
markers data will be conducted with the aim of hypoth-
esis generation. First of all, a complete description of
data from biological and pharmacogenomic studies will
be done. For biomarkers that might change over time as
a consequence of treatment, levels before and after treat-
ment will be compared with appropriate statistical tests,
based on the type of data. Serum levels of VPA through-
out treatment will be described and compared between
different acetylator phenotypes, with appropriate statis-
tical tests. P values ≤0.05 will be considered significant,
and no adjustment is planned for multiple comparisons
due to the exploratory nature of the analysis.
Quality assurance and data collection procedures
The procedures set out in this study protocol are de-
signed to ensure that the principles of the Good Clinical
Practice guidelines of the International Conference on
Harmonization (ICH) and the Declaration of Helsinki
are respected in the conduct, evaluation and documenta-
tion of this study. Patient registration and data collection
are centralized at the National Cancer Institute of
Naples. Biological analyses are centralized at the Experi-
mental Pharmacology Unit of the NCI of Naples.
Discussion
In spite of improvements in the treatment of squamous
cell carcinoma of the head and neck, the prognosis of pa-
tients with recurrent/metastatic disease remains poor. The
goal of V-CHANCE study is to demonstrate the feasibility
and efficacy of cisplatin/CTX plus VPA to provide a less
toxic and more effective first line chemotherapy regimen
in patients with R/M SCCHN. The choice of VPA as add-
itional drug in patients treated with cisplatin and CTX
should provide a three- drug regimen whose toxicity
should not exceed that of the standard two-drug regimen.
A new three-drug regimen to be considered less toxic
than the 5-fluorouracil-containing other standard, adding
a safe and low cost generic drug with HDACi activity such
as VPA to the doublet cisplatin-CTX.
Furthermore, the correlative studies could identify poten-
tial appealing prognostic/predictive biomarkers of toxicity
and efficacy adding also new insight in the mechanism of
interaction between VPA, cisplatin and CTX.
Overall, this study is basically aimed at finding out
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CTX: Cetuximab; DCR: Disease control rate; DLT: Dose limiting toxicity;
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GCP: Good clinical practice; HDACi: Histone deacetylase inhibitors; HPV: Human
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resonance imaging; MTD: Maximum tolerated dose; ORR: Overall response
rate; PBMC: Peripheral blood mononuclear cells; PD: Progressive disease;
PFS: Progression free survival; PR: Partial response; PS: Performance status;
PVCs: Premature ventricular contractions; R/M: Recurrent/Metastatic;
RECIST: Response evaluation criteria in solid tumors; SCCHN: Squamous cell
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